PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2011 | 6 | 5 | 608-615
Tytuł artykułu

Investigating gene expression profile of non-small cell lung cancer

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Lung cancer is mainly a lifestyle-associated disease with poor prognosis and the lowest five year survival rate of all types of cancer. Lung cancers are divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Surgical treatment is generally indicated in cases of early stage NSCLC, and those patients treated with radical and aggressive surgery have a somewhat better survival rate. The main problems with lung cancer treatment are due to late diagnosis, rapidly developing drug resistance and side effects of the treatment that are experienced by almost all patients. The next step for distinguishing histologically complicated lung cancers and determining optimal treatment strategies is gene expression analysis. Supported by gene expression data, it is possible to prognosticate the course of the disease.
Wydawca
Czasopismo
Rocznik
Tom
6
Numer
5
Strony
608-615
Opis fizyczny
Daty
wydano
2011-10-01
online
2011-08-09
Bibliografia
  • [1] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul–Aug;59(4):225–249 http://dx.doi.org/10.3322/caac.20006[Crossref]
  • [2] Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer. 2004 Dec 15;101(12):2843–2850 http://dx.doi.org/10.1002/cncr.20666[Crossref]
  • [3] Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007 Jan;12(1):20–37 http://dx.doi.org/10.1634/theoncologist.12-1-20[Crossref]
  • [4] Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999 Nov 1;86(9):1867–1876 http://dx.doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9[Crossref]
  • [5] Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005 May 10;23(14):3175–3185 http://dx.doi.org/10.1200/JCO.2005.10.462[Crossref]
  • [6] Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001 Dec;18(6):1059–1068 http://dx.doi.org/10.1183/09031936.01.00275301[Crossref]
  • [7] Anbazhagan R, Tihan T, Bornman DM, Johnston JC, Saltz JH, Weigering A, et al. Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res. 1999 Oct 15;59(20):5119–5122
  • [8] Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest. 1994 Dec;106(6 Suppl):367S–371S http://dx.doi.org/10.1378/chest.106.6.367S[Crossref]
  • [9] Okubo C, Minami Y, Tanaka R, Uchihara T, Anami Y, Furuya S, et al. Analysis of differentially expressed genes in neuroendocrine carcinomas of the lung. J Thorac Oncol. 2006 Oct;1(8):780–786 http://dx.doi.org/10.1097/01243894-200610000-00005[Crossref]
  • [10] Wistuba, II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000 Jul;6(7):2604–2610
  • [11] Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet. 2007 Aug;8(8):601–609 http://dx.doi.org/10.1038/nrg2137[WoS][Crossref]
  • [12] Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, et al. Expression of gemcitabine- and cisplatin-related genes in nonsmall-cell lung cancer. The pharmacogenomics journal. 2009 Nov 10 [WoS]
  • [13] Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006 Aug 1;66(15):7466–7472 http://dx.doi.org/10.1158/0008-5472.CAN-06-1191[Crossref]
  • [14] Gray J, Simon G, Bepler G. Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2007 Apr;7(4):545–549 http://dx.doi.org/10.1586/14737140.7.4.545[Crossref][WoS]
  • [15] Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503–511 http://dx.doi.org/10.1038/35000501[Crossref]
  • [16] Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790–13795 http://dx.doi.org/10.1073/pnas.191502998[Crossref]
  • [17] van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 19;347(25):1999–2009 http://dx.doi.org/10.1056/NEJMoa021967[Crossref]
  • [18] Cooper D. The Molecular Genetics of Lung Cancer. Heidelberg: Springer-Verlag 2005
  • [19] Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest. 2005 Jul;128(1):370–381 http://dx.doi.org/10.1378/chest.128.1.370[Crossref]
  • [20] Dennis JL, Vass JK, Wit EC, Keith WN, Oien KA. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res. 2002 Nov 1;62(21):5999–6005
  • [21] Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol. 2001 Oct;159(4):1231–1238 http://dx.doi.org/10.1016/S0002-9440(10)62509-6[Crossref]
  • [22] Vooder T, Valk K, Kolde R, Roosipuu R, Vilo J, Metspalu A. Gene Expression-Based Approaches in Differentiation of Metastases and Second Primary Tumour. Case Rep Oncol.3(2):255–261
  • [23] Bridgewater J, van Laar R, Floore A, Van TVL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British journal of cancer. 2008 Apr 22;98(8):1425–1430 http://dx.doi.org/10.1038/sj.bjc.6604315[Crossref]
  • [24] Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002 Jun 1;62(11):3005–3008
  • [25] Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002 Aug; 8(8):816–824
  • [26] Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest. 2007 Oct 18
  • [27] Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006 Dec;3(12):e467 http://dx.doi.org/10.1371/journal.pmed.0030467[Crossref]
  • [28] Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007 Feb 22;356(8):800–808 http://dx.doi.org/10.1056/NEJMoa065411[Crossref]
  • [29] Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 2004 Jul 8;23(31):5360–5370 http://dx.doi.org/10.1038/sj.onc.1207697[Crossref]
  • [30] Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007 Jan 4;356(1):11–20 http://dx.doi.org/10.1056/NEJMoa060096[Crossref][WoS]
  • [31] Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol. 2007 Dec 10;25(35):5562–5569 http://dx.doi.org/10.1200/JCO.2007.12.0352[Crossref]
  • [32] Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003 Oct;3(10):733–744 http://dx.doi.org/10.1038/nrc1190[Crossref]
  • [33] Powell CA, Spira A, Derti A, DeLisi C, Liu G, Borczuk A, et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol. 2003 Aug;29(2):157–162 http://dx.doi.org/10.1165/rcmb.2002-0183RC[Crossref]
  • [34] Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):29S–55S http://dx.doi.org/10.1378/chest.07-1347[Crossref]
  • [35] Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006 May 10;24(14):2158–2163 http://dx.doi.org/10.1200/JCO.2006.06.5961[Crossref]
  • [36] Cerfolio RJ, Bryant AS, Scott E, Sharma M, Robert F, Spencer SA, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest. 2006 Dec;130(6):1796–1802 http://dx.doi.org/10.1378/chest.130.6.1796[Crossref]
  • [37] Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Differential expression of biomarkers in men and women. Seminars in oncology. 2009 Dec;36(6):553–565 http://dx.doi.org/10.1053/j.seminoncol.2009.09.004[Crossref][WoS]
  • [38] Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000 Nov 1;92(21):1764–1772 http://dx.doi.org/10.1093/jnci/92.21.1764[Crossref]
  • [39] Wei Z, Lifen J, Jiliang H, Jianlin L, Baohong W, Hongping D. Detecting DNA repair capacity of peripheral lymphocytes from cancer patients with UVC challenge test and bleomycin challenge test. Mutagenesis. 2005 Jul;20(4):271–277 http://dx.doi.org/10.1093/mutage/gei037[Crossref]
  • [40] Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983–991 http://dx.doi.org/10.1056/NEJMoa060570[Crossref]
  • [41] Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy. Clin Cancer Res. 2004 Aug 1;10(15):4939–4943 http://dx.doi.org/10.1158/1078-0432.CCR-04-0247[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-011-0063-8
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.